middle.news
Noxopharm Signs New Global MTAs and Boosts Cash with $2.34M R&D Rebate
7:03pm on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Noxopharm Signs New Global MTAs and Boosts Cash with $2.34M R&D Rebate
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Multiple new MTAs signed with overseas companies validating Sofra platform
Second-round studies underway with existing collaborators
SOF-SKN clinical trial preparations advance with CRO and manufacturer contracts
Received $2.34 million R&D tax rebate enhancing cash reserves
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE